H. Lundbeck A/S (HLUYY) Stock Price, News & Analysis

Company Overview

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.

Key Stats

• Today's Range: $22.00 to $24.00
• 50-Day Range: $22.00 to $22.00
• 52-Week Range: $10.00 to $31.55
• Volume: 7,500 shs
• Average Volume: 1,758 shs
• Market Capitalization: $21.91 billion
• P/E Ratio: 25.00
• Dividend Yield: 0.91%
• Price Target: N/A
• Consensus Rating: N/A

HLUYY Stock Analysis - Frequently Asked Questions

How have HLUYY shares performed this year?

H. Lundbeck A/S's stock was trading at $22.00 at the start of the year. Since then, HLUYY stock has increased by 0.0% and is now trading at $22.00.
View the best growth stocks for 2025 here.

How were H. Lundbeck A/S's earnings last quarter?

H. Lundbeck A/S (OTCMKTS:HLUYY) released its quarterly earnings results on Wednesday, November, 4th. The company reported $0.17 EPS for the quarter, topping analysts' consensus estimates of $0.01 by $0.16. The company had revenue of $547.05 million for the quarter, compared to analysts' expectations of $514.82 million. H. Lundbeck A/S had a trailing twelve-month return on equity of 13.74% and a net margin of 6.74%.

Does H. Lundbeck A/S have any subsidiaries?

The following companies are subsidiaries of H. Lundbeck A/S: Alder BioPharmaceuticals, and Prexton Therapeutics.

How do I buy shares of H. Lundbeck A/S?

Shares of HLUYY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 11/04/2015
• Today: 5/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Private Households
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:HLUYY
• CIK: N/A
• Web: www.lundbeck.com
• Phone: (453) 630-1311
• Fax: 45-3630-1940
• Employees: 5,348
• Year Founded: 1915

Profitability

• EPS (Most Recent Fiscal Year): $0.88
• Trailing P/E Ratio: 25.00
• Forward P/E Ratio: 10.48
• P/E Growth: N/A
• Net Income: $209.69 million
• Net Margins: 6.74%
• Pretax Margin: 7.83%
• Return on Equity: 13.74%
• Return on Assets: 7.16%

Debt

• Debt-to-Equity Ratio: 0.32
• Current Ratio: 1.15
• Quick Ratio: 0.71

Sales & Book Value

• Annual Sales: $2.59 billion
• Price / Sales: 8.45
• Cash Flow: $3.36 per share
• Price / Cash Flow: 6.54
• Book Value: $14.60 per share
• Price / Book: 1.51

Miscellaneous

• Outstanding Shares: 995,741,000
• Free Float: N/A
• Market Cap: $21.91 billion
• Optionable: Not Optionable
• Beta: 0.68